Positive rate and prognostic significance of the superb microvascular imaging signal in joints of rheumatoid arthritis patients in remission with normal C-reactive protein levels and erythrocyte sedimentation rates.
Inflammatory marker
Prognosis
Rheumatoid arthritis
Superb microvascular imaging
Ultrasound
Journal
Journal of medical ultrasonics (2001)
ISSN: 1613-2254
Titre abrégé: J Med Ultrason (2001)
Pays: Japan
ID NLM: 101128385
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
03
02
2021
accepted:
07
05
2021
pubmed:
21
5
2021
medline:
7
10
2021
entrez:
20
5
2021
Statut:
ppublish
Résumé
This study aimed to evaluate the positive rate and prognostic significance of superb microvascular imaging (SMI) in rheumatoid arthritis (RA) patients in remission with normal C-reactive protein (CRP) levels and erythrocyte sedimentation rates (ESR). The study enrolled 112 RA patients, and ultrasound (US) assessment was performed on 28 joints of each patient. The SMI signal-positive rates for each joint were: metacarpophalangeal (MCP) joints: 20.5%, wrist joints: 43.8%, metatarsophalangeal (MTP) joints: 17.0%, and other foot joints: 25.0%. Investigation of the prognostic significance of the SMI signal in each joint revealed that only in the MTP joints was the total score of the SMI signal in the patients with relapse significantly higher than that in the patients with remission (P = 0.01). Comparison of the receiver operating characteristics curves for predicting relapse showed that the area under the curve (AUC) of the MTP joints was the highest (AUC = 0.66) of the investigated joints. The optimal threshold for the total MTP SMI score was 1 (accuracy = 83.3%). Positive/negative data of the SMI signal in the MTP joints were not significantly associated with the values of conventional disease activity markers. In RA patients in remission with normal CRP and ESR levels, the percentage of positive SMI signal was highest in the wrist joints. However, the accuracy of the SMI signal for predicting relapse was greatest for the MTP joints, suggesting that US assessment of the MTP joints by SMI is useful for predicting relapse in these patients.
Identifiants
pubmed: 34014426
doi: 10.1007/s10396-021-01102-5
pii: 10.1007/s10396-021-01102-5
doi:
Substances chimiques
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
353-359Subventions
Organisme : Japan Society for the Promotion of Science
ID : 18K12103
Informations de copyright
© 2021. The Japan Society of Ultrasonics in Medicine.
Références
Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388:2023–38.
doi: 10.1016/S0140-6736(16)30173-8
Aga AB, Lie E, Uhlig T, et al. Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000–2010. Ann Rheum Dis. 2015;74:381–8.
doi: 10.1136/annrheumdis-2013-204020
Bechman K, Tweehuysen L, Garrood T, et al. Flares in rheumatoid arthritis patients with low disease activity: predictability and association with worse clinical outcomes. J Rheumatol. 2018;45:1515–21.
doi: 10.3899/jrheum.171375
Goekoop-Ruiterman YP, Huizinga TW. Rheumatoid arthritis: can we achieve true drug-free remission in patients with RA? Nat Rev Rheumatol. 2010;6:68–70.
doi: 10.1038/nrrheum.2009.253
Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79:685–99.
doi: 10.1136/annrheumdis-2019-216655
Vastesaeger N, Xu S, Aletaha D, et al. A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology (Oxford). 2009;48:1114–21.
doi: 10.1093/rheumatology/kep155
Wells G, Becker JC, Teng J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League against rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis. 2009;68:954–60.
doi: 10.1136/ard.2007.084459
Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis. 2011;70:404–13.
doi: 10.1136/ard.2011.149765
Ohrndorf S, Backhaus M. Advances in sonographic scoring of rheumatoid arthritis. Ann Rheum Dis. 2013;72:ii69-75.
doi: 10.1136/annrheumdis-2012-202197
Scirè CA, Montecucco C, Codullo V, et al. Ultrasonographic evaluation of joint involvement in early rheumatoid arthritis in clinical remission: power Doppler signal predicts short-term relapse. Rheumatology (Oxford). 2009;48:1092–7.
doi: 10.1093/rheumatology/kep171
Peluso G, Michelutti A, Bosello S, et al. Clinical and ultrasonographic remission determines different chances of relapse in early and long standing rheumatoid arthritis. Ann Rheum Dis. 2011;70:172–5.
doi: 10.1136/ard.2010.129924
Foltz V, Gandjbakhch F, Etchepare F, et al. Power Doppler ultrasound, but not low-field magnetic resonance imaging, predicts relapse and radiographic disease progression in rheumatoid arthritis patients with low levels of disease activity. Arthritis Rheum. 2012;64:67–76.
doi: 10.1002/art.33312
Yoshimi R, Hama M, Takase K, et al. Ultrasonography is a potent tool for the prediction of progressive joint destruction during clinical remission of rheumatoid arthritis. Mod Rheumatol. 2013;23:456–65.
doi: 10.3109/s10165-012-0690-1
Iwamoto T, Ikeda K, Hosokawa J, et al. Prediction of relapse after discontinuation of biologic agents by ultrasonographic assessment in patients with rheumatoid arthritis in clinical remission: high predictive values of total gray-scale and power Doppler scores that represent residual synovial inflammation before discontinuation. Arthritis Care Res. 2014;66:1576–81.
doi: 10.1002/acr.22303
Nguyen H, Ruyssen-Witrand A, Gandjbakhch F, et al. Prevalence of ultrasound-detected residual synovitis and risk of relapse and structural progression in rheumatoid arthritis patients in clinical remission: a systematic review and meta-analysis. Rheumatology (Oxford). 2014;53:2110–8.
doi: 10.1093/rheumatology/keu217
Han J, Geng Y, Deng X, Zhang Z. Subclinical synovitis assessed by ultrasound predicts flare and progressive bone erosion in rheumatoid arthritis patients with clinical remission: a systematic review and metaanalysis. J Rheumatol. 2016;43:2010–8.
doi: 10.3899/jrheum.160193
Kawashiri SY, Fujikawa K, Nishino A, et al. Ultrasound-detected bone erosion is a relapse risk factor after discontinuation of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis whose ultrasound power Doppler synovitis activity and clinical disease activity are well controlled. Arthritis Res Ther. 2017;19:108.
doi: 10.1186/s13075-017-1320-2
Matsuo H, Imamura A, Shimizu M, et al. Prediction of recurrence and remission using superb microvascular imaging in rheumatoid arthritis. J Med Ultrason (2001). 2020;47:131–8.
doi: 10.1007/s10396-019-00978-8
Naredo E, Valor L, De la Torre I, et al. Ultrasound joint inflammation in rheumatoid arthritis in clinical remission: how many and which joints should be assessed? Arthritis Care Res (Hoboken). 2013;65:512–7.
doi: 10.1002/acr.21869
Backhaus M, Burmester GR, Gerber T, et al. Guidelines for musculoskeletal ultrasound in rheumatology. Ann Rheum Dis. 2001;60:641–9.
doi: 10.1136/ard.60.7.641
Szkudlarek M, Court-Payen M, Jacobsen S, et al. Interobserver agreement in ultrasonography of the finger and toe joints in rheumatoid arthritis. Arthritis Rheum. 2003;48:955–62.
doi: 10.1002/art.10877
Sun X, Deng X, Xie W, et al. The agreement between ultrasound-determined joint inflammation and clinical signs in patients with rheumatoid arthritis. Arthritis Res Ther. 2019;21:100.
doi: 10.1186/s13075-019-1892-0
Terslev L, Torp-Pedersen S, Qvistgaard E, et al. Doppler ultrasound findings in healthy wrists and finger joints. Ann Rheum Dis. 2004;63:644–8.
doi: 10.1136/ard.2003.009548
Dalal DS, Zhang T, Shireman TI. Medicare expenditures for conventional and biologic disease-modifying agents commonly used for the treatment of rheumatoid arthritis. Semin Arthritis Rheum. 2020;50:822–6.
doi: 10.1016/j.semarthrit.2020.08.002
Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA. 2018;320:1360–72.
doi: 10.1001/jama.2018.13103
Kawahara R, Nakabo S, Shimizu M, et al. Feasibility of patient-oriented ultrasound joint selection: Cross-sectional observational study on rheumatoid arthritis. Mod Rheumatol. 2020;30:975–81.
doi: 10.1080/14397595.2019.1680095